Several other research analysts also recently commented on the company. Barclays reiterated an overweight rating on shares of AstraZeneca in a research note on Tuesday, October 9th. Shore Capital reiterated a hold rating on shares of AstraZeneca in a research note on Friday, September 7th. Jefferies Financial Group reiterated a hold rating and set a GBX 5,800 ($75.79) target price on shares of AstraZeneca in a research note on Friday, October 12th. Credit Suisse Group set a GBX 6,350 ($82.97) target price on AstraZeneca and gave the stock a buy rating in a research note on Thursday, August 30th. Finally, Citigroup reiterated a buy rating and set a GBX 6,200 ($81.01) target price on shares of AstraZeneca in a research note on Tuesday, September 25th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. AstraZeneca currently has a consensus rating of Hold and an average price target of GBX 5,831.89 ($76.20).
Shares of LON AZN traded up GBX 79 ($1.03) during midday trading on Friday, hitting GBX 6,172 ($80.65). 2,861,442 shares of the company’s stock were exchanged, compared to its average volume of 2,310,000. AstraZeneca has a 12 month low of GBX 4,260 ($55.66) and a 12 month high of GBX 5,520 ($72.13).
AstraZeneca Company Profile
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.